Jim Simons acquired 2.5 Million Neurocrine Biosciences shares worth $313 Million. That's 0.46% of their equity portfolio (28th largest holding). The investor owns 2.54% of the outstanding Neurocrine Biosciences stock. The first Neurocrine Biosciences trade was made in Q3 2015. Since then Jim Simons bought shares sixteen more times and sold shares on fourteen occasions. The stake costed the investor $279 Million, netting the investor a gain of 12% so far.